Vaccine compositions having improved stability and immunogenicity
US-12257297-B2 · Mar 25, 2025 · US
Demonstrated in vivo effect
Demonstrated in vivo effect · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N2760/14171 |
| Official title | Demonstrated in vivo effect |
| Display label | Demonstrated in vivo effect |
| Total patents | 33 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is rapidly declining.
| Year | Patents |
|---|---|
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Adjuvant and vaccine containing adjuvant
US-2024261398-A1 · Aug 8, 2024 · US
Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same
US-2024100143-A1 · Mar 28, 2024 · US
Methods and compositions for inducing protective immunity against filovirus infection
US-11918639-B2 · Mar 5, 2024 · US
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US-11723969-B2 · Aug 15, 2023 · US
Adjuvant and vaccine containing adjuvant
US-2023210987-A1 · Jul 6, 2023 · US
Vaccine compositions having improved stability and immunogenicity
US-2022387579-A1 · Dec 8, 2022 · US
Vaccine compositions having improved stability and immunogenicity
US-11364294-B2 · Jun 21, 2022 · US
Virus-like particles and uses thereof
US-2022184200-A1 · Jun 16, 2022 · US
Methods and compositions for inducing protective immunity against filovirus infection
US-2022088170-A1 · Mar 24, 2022 · US
Vaccine compositions having improved stability and immunogenicity
US-11253585-B2 · Feb 22, 2022 · US
Methods and compositions for inducing protective immunity against filovirus infection
US-11173201-B2 · Nov 16, 2021 · US
Immune activation triggered by filovirus proteins and polypeptides
US-2021171581-A1 · Jun 10, 2021 · US
Adjuvant and vaccine containing adjuvant
US-2021106680-A1 · Apr 15, 2021 · US
Methods and compositions for inducing protective immunity against a Marburg virus infection
US-10925955-B2 · Feb 23, 2021 · US
Methods and compositions for inducing protective immunity against a marburg virus infection
US-10925956-B2 · Feb 23, 2021 · US
Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same
US-2020390880-A1 · Dec 17, 2020 · US
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US-10765733-B2 · Sep 8, 2020 · US
Methods and compositions for inducing protective immunity against a marburg virus infection
US-2020113994-A1 · Apr 16, 2020 · US
Vaccine compositions having improved stability and immunogenicity
US-2020101151-A1 · Apr 2, 2020 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N2760/14171?
- CPC C12N2760/14171 is the Cooperative Patent Classification code for “Demonstrated in vivo effect.”
- How many patents are filed under CPC C12N2760/14171 (Demonstrated in vivo effect)?
- Our database includes 33 publications tagged with this CPC code.
- Is patent activity under CPC C12N2760/14171 growing?
- Publication counts under this code: 3 in 2024 vs 1 in 2025 (latest complete years).